Announcements Trials
Browse Landscape

Phase

Phase 3 21Phase 2 13Phase NA 5Phase 2/3 3Phase 1 3Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Vomiting 2Nausea 2Postoperative Nausea and Vomiting 1Neoplasms 1Muscular Atrophy 1Child Nutrition Disorders 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Olanzapine × Clear all
NCT06175273 2025-09-18

POINT

University of Kentucky

Phase 2/3 Completed
19 enrolled

Muscular Atrophy, Neoplasms, Child Nutrition Disorders

NCT03631004 2022-01-13

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Instituto do Cancer do Estado de São Paulo

Phase 2/3 Completed
100 enrolled

Nausea, Vomiting, Postoperative Nausea and Vomiting

NCT03137121 2021-08-17

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

University of Alabama at Birmingham

Phase 2/3 Completed
30 enrolled 9 charts

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡